In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1839 News Items found
Honors
Zeda Zhang
GSK Student Wins NCI Award to Pursue Innovative Prostate Cancer Research

Zeda Zhang was recently awarded the Predoctoral to Postdoctoral Fellow Transition Award from the National Cancer Institute (NCI).
Feature
elderly patient and caregiver
9 Tips for Caregivers: How to Help a Loved One with Cancer

Hear from members of the MSK community who have cared for a loved one with cancer.
Announcement
Gloved hand and magnifying glass on banded DNA sequences
FDA Authorizes MSK-IMPACT Test for Analyzing Patient Tumors

The test, developed at MSK, looks for alterations in 468 genes that are seen in both common and rare cancers.
Science Byte
Prostate cancer cells, colored red in scanning electron micrograph (SEM).
PSMA: A New Target for Prostate Cancer Treatment

Researchers have discovered how a high level of the protein PSMA in cells helps fuel prostate cancer.
Q&A
MSK Director of Breast Pathology Edi Brogi
A Brief Guide to Breast Cancer Pathology and Second Opinions

Breast pathologist Edi Brogi explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease.
Feature
Former MSK president Paul Marks
The Man behind the Prize: How Paul Marks Shaped Modern Cancer Research

Recent advances in epigenetic and targeted therapies owe a lot to the foresight of former MSK President Paul Marks, who believed in the importance of basic research.
Feature
Thanksgiving dinner
How to Cope with Holiday Stress When You Have Cancer

Read our suggestions for getting through the holiday season while facing cancer.
FDA Announces First Approval of Targeted Therapy Based on Basket Study

The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever drug approved for ECD, a rare blood disorder. This landmark approval came as a direct result of research at Memorial Sloan Kettering Cancer Center (MSK).
In the Lab
iron-filled macrophages from a breast cancer tumor
MSK-Developed Technology Provides a “Virtual Biopsy” of Immune Cells in Tumors

The noninvasive approach could help scientists track the movements of an important cell type that can influence the outcome of cancer treatment.
Science Byte
Cancer biologist and pediatric oncologist Alex Kentsis
Blocking Enzymes That Signal DNA Damage Could Be a Treatment Strategy for Childhood Cancers

A new strategy for treating pediatric cancers involves preventing cells from repairing their own DNA.